Please log in for more information
The Xpress Pharmaceutics™ service has been designed to accelerate development of oral drugs through Phase 1 clinical studies. By integrating formulation development, on-demand clinical manufacturing, regulatory support and clinical testing, the approach can reduce both the cost and time taken to complete first-in-human trials.
Xpress Pharmaceutics allows Catalent to work alongside innovator and clinical research organizations, and provide formulated clinical trial material in line with adaptive study protocols, providing a faster alternative to traditional clinical development models, and offering the advantage of flexible dose and/or formulation composition adjustment during a clinical trial, guided by real-time clinical data.